Syndax Pharmaceuticals $SNDX plunges 17% after its drug axatilimab flopped in a Phase 2 lung scarring trial, missing its primary endpoint, the main goal. Syndax drops that use. Its approved drug and cancer drug Revuforj are untouched. @petenajarian @jonnajarian weigh the fallout because #ITSNOTANOPTION 📙 RebelCon 2026 Oct 19-21 Vegas 👉 https://t.co/3C7PXfQHvx
View on X ↗